Recombinant Human ST6GAL1 (C500)
产品说明(Description)
Recombinant Human beta-Galactoside alpha-2,6-Sialyltransferase 1 is produced by our Mammalian expression system and the target gene encoding Lys27-Cys406 is expressed with a 6His tag at the C-terminus.
Accession #: P15907
Known as: Beta-Galactoside Alpha-2;6-Sialyltransferase 1; Alpha 2;6-ST 1; B-Cell Antigen CD75; CMP-N-Acetylneuraminate-Beta-Galactosamide-Alpha-2;6-Sialyltransferase 1; ST6Gal I; ST6GalI; Sialyltransferase 1; ST6GAL1; SIAT1
制剂(Formulation)
Supplied as a 0.2 μm filtered solution of 20mM TrisHCl, 150mM NaCl, pH 8.0.
质量控制(Quality Control)
Purity: Greater than 95% as determined by reducing SDS-PAGE.
Endotoxin: Less than 0.1 ng/ug (1 EU/ug) as determined by LAL test.
运输(Shipping)
The product is shipped on dry ice/polar packs.
Upon receipt, store it immediately at the temperature listed below.
保存(Storage)
Store at ≤-70°C, stable for 6 months after receipt.
Store at ≤-70°C, stable for 3 months under sterile conditions after opening.
Please minimize freeze-thaw cycles.
背景(Background)
The ST6GAL1 gene encodes β-Galactosamide α-2,6-Sialyltransferase 1. It is a type II membrane protein and is localized to the trans-Golgi network. It catalyzes 2,6-sialylation of Galβ1,4-GlcNAc structures on N-glycans. ST6GAL1 is highly expressed in the liver and other tissues. ST6GAL1 deficiency causes abnormalities in B-cell immunoreactivity. The expression and activity of ST6GAL1 are associated with tumor metastasis in breast and colon cancers. The majority of ST6GAL1 in the liver is cleaved and secreted into the serum and may be used as a biomarker for hepatitis diseases.
电泳(SDS-PAGE)
FOR RESEARCH USE ONLY